Abstract
Background
Aim of the present study was to ascertain if a combination of leukocyte and platelet‐rich fibrin (L‐PRF) + autogenous bone graft (ABG) may be a clinically “non‐inferior” treatment modality as compared with the association of Enamel Matrix Derivative (EMD) with ABG in the management of intrabony defects (IBDs).
Methods
Forty‐four patients, exhibiting at least one unfavourable intraosseous defect, were treated by L‐PRF associated with ABG (22 patients; test group) or EMD+ABG (control group) in each defect. At baseline and 12 months, a complete clinical and radiographic examination was done. Pre‐ and post‐therapy clinical (probing pocket depth [PPD], clinical attachment level [CAL], gingival recession [GR]) and radiographic (defect Bone level [(DBL)] parameters for the different treatments were compared. To guarantee the test treatment's efficacy 1mm was chosen as non‐inferiority margin; for clinical relevance, a second non‐inferiority margin = 0.5mm was set.
Results
Clinical and radiographic parameters significantly improved 12 months after surgery in both test and control sites, without inter‐groups differences for each measurement. The control group – test group differences for the parameters CAL gain ‐0.248mm (‐0.618 to 0.122), PPD Reduction ‐0.397mm (‐0.810 to 0.015), GR Change 0.059mm (‐0.300 to 0.418), DBL Gain ‐0.250mm (‐0.746 to 0.246) were all within the non‐inferiority margin of 0.5 mm.
Conclusion
Our results suggest that the L‐PRF+ABG combined treatment of non‐contained intrabony defects produces non‐inferior results in terms of CAL gain, PPD reduction, GR increase and DBL gain in comparison with the EMD+ABG combination.
This article is protected by copyright. All rights reserved
from
https://onlinelibrary.wiley.com/doi/abs/10.1002/JPER.19-0533?af=R
No comments:
Post a Comment